Wall Street Zen Upgrades Inovio Pharmaceuticals (NASDAQ:INO) to Hold

Inovio Pharmaceuticals (NASDAQ:INO) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other research firms have also commented on INO. Weiss Ratings lowered Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. HC Wainwright restated a “neutral” rating on shares of Inovio Pharmaceuticals in a research report on Thursday. Piper Sandler reaffirmed an “overweight” rating and issued a $4.00 target price on shares of Inovio Pharmaceuticals in a report on Monday, August 3rd. Jefferies Financial Group raised shares of Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and lifted their target price for the company from $1.80 to $3.00 in a report on Thursday. Finally, Zacks Research upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $3.17.

Inovio Pharmaceuticals Price Performance

NASDAQ:INO opened at $1.09 on Friday. The business’s 50 day moving average is $1.03 and its two-hundred day moving average is $1.30. Inovio Pharmaceuticals has a 52 week low of $0.56 and a 52 week high of $2.98. The company has a market cap of $112.71 million, a PE ratio of -1.20 and a beta of 1.52.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.15. As a group, sell-side analysts expect that Inovio Pharmaceuticals will post -0.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Focus Partners Wealth purchased a new stake in shares of Inovio Pharmaceuticals during the third quarter worth approximately $33,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 5,894 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in Inovio Pharmaceuticals by 752.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 18,160 shares during the last quarter. Raymond James Financial Inc. increased its stake in Inovio Pharmaceuticals by 4,396.0% in the 3rd quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 16,309 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Inovio Pharmaceuticals in the 3rd quarter valued at $41,000. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.